Welcome to New Orleans

Old favorites and new programming provide robust experience

Welcome to the AAD’s Annual Meeting 2023. This is the first time AAD has been in the Big Easy since 2011. Each day of the meeting, attendees can access new lectures and presentations and revisit some perennial favorites. Explore more than 50 new titles, including:

- U054 – Pearls from Complex Mohs
- U055 – Advances in Microneedling Techniques Around the World
- S058 – Alopecia Areata: New Therapies
- F120 – Great Debates in Medical Dermatology
- U088 – When to Put Down the Scalpel: Non-surgical Therapies for Skin Cancer
- U090 – Technology in Dermatology: Tailoring Solutions to Your Practice and Optimizing Joy & Impact

Today, highlights include two new live demonstration courses, and two new Conquer the Boards sessions have been included, as part of the many offerings for residents. Don’t forget to stop by the AAD Career Networking Event today as well, from 4:30–5:30 p.m. at the Hilton New Orleans Riverside – Grand Ballroom C. There’s also a DataDerm™ Registry and Refreshments event today from 5:30–6:30 p.m. in the Convention Center Foyer Room 338.

On Saturday, March 18, there are two handheld courses offered. One is also the day to catch the two Late-Breaking Research sessions. A new SO30 – Boards Blitz session is scheduled for Saturday as well.

Sunday, March 19 features the return of the P35 – Plenary with several exciting speakers and guest lecturer Safi Bahcall. On Sunday afternoon, attendees can look forward to the latest SO48 – Hot Topics session, a new SO44 – Skin of Color session, and a new round of SO45 – Resident Jeopardy.

On Monday, March 20, there are several new return courses, and several new and returning sessions. The meeting closes on Tuesday, but not without two favorites. SO59 – What’s New in Dermatology, and SO60 – Therapeutic and Diagnostic Pearls. That’s just the very tip of the iceberg. With more than 300 educational sessions, each day the AAD offers scores of symposiums, focus sessions, courses, and workshops, covering all aspects of your practice from treatment pearls to practice management. Use the AAD mobile app to explore the program and track your favorites.

And when you’re not in sessions or exploring New Orleans, be sure to visit the always-vibrant Exhibit Hall and AAD Resource Center in the Hilton New Orleans Riverside, from 4:30-6:30 p.m.

See More DermWorld Meeting News! aadmeeetingnews.org

Interact with the AAD’s Preferred Providers

We’ve aligned with companies who can provide solutions for your life in and out of the office. Stop by their booths in the Exhibit Hall to learn more!

- AAD Member Buying Program, Booth 4543
- Bank of America Practice Solutions, Booth 930
- CareCredit, Booth 3613
- Medjet, Booth 1065
- Medline Industries, LP, Booth 4629
- VisualDx, Booth 2838

For a full list of our providers, visit aad.org/preferredproviders

Don’t Miss the AAD Career Networking Event – Hosted by AAD Career Compass

Friday, March 17 • 4:30 – 6:30 p.m., Hilton New Orleans Riverside Hotel, Grand Ballroom C
Combat staffing shortages

WOW! “THAT’S A RELIEF!”

We hear it often when practices see our software for the first time. So often that we named it. They’re called WOW Moments and it’s when you realize you don’t have to compromise and live with the limitations of your outdated system any longer.

For Dawn Ricker of Dermatologic Surgery Center of Northeast Ohio, Inc., her WOW Moment was watching system-generated recalls decrease staffing demands:

“Instead of our staff calling, emailing and texting patients, the Patient Reminder functionality automates this process. As a result, we’ve saved hours of time.”

#1 Integrated derm-specific EHR, PM & RCM Solution®
+ Analytics + Patient Engagement

What will your WOW Moment be?
Find out at BOOTH #4239 and enter to win an Apple Watch
modmed.com/aad-meeting | 561.235.7501

*2023 Black Book™ | ©2023 Modernizing Medicine, Inc.*
The kids are alright, if you know how to treat them

Pediatric dermatology through adult eyes

Although many skin disorders are diagnosed in patients of all ages, some are more common or present differently in children than adults. For example, atopic dermatitis is one of the most common diseases of childhood. In addition to more typical flexural involvement, it can present with follicular prominence, in association with pityriasis alba, or with periorbital distribution in children, according to Valerie Margaret Carlberg, MD, FAAD, assistant professor of dermatology at the Medical College of Wisconsin in Milwaukee and medical director of its Vascular Anomalies Program.

“Little creatures in a big world”

“There is an expression that children are just little adults; however, we know this isn’t true,” Dr. Carlberg said. “For example, the most common triggers of allergic contact dermatitis in children differ from those in adults due to differences in environmental exposures between these unique patient populations.”

Contact dermatitis is one of several dermatologic conditions that speakers will explore during the session. Other concerns include atopic dermatitis, acne fulminans, hidradenitis suppurativa, as well as unique diagnostic and treatment considerations for pediatric patients.

Child-centric approach

To help dermatologists identify and treat skin conditions in children, speakers will guide attendees through a child-centric approach for several of the disorders. The key, Dr. Carlberg said, is understanding the unique differential diagnosis for skin conditions and the challenges of treatment in this age group. Appropriately managing pediatric patients with skin disease requires a special emphasis on knowledge of natural history/ outcomes and optimal treatment strategies for this population.

“There are many nuances between treatment selections in children and adults. Many of the treatments that are FDA approved for dermatologic conditions in adults are not yet approved for use in pediatric patients,” Dr. Carlberg said. “This is primarily due to the lack of inclusion of younger patients in the initial clinical trials evaluating the safety and efficacy of a medication. Thus, treatments are often used off-label until clinical trials in children are completed. Lack of FDA approval can create challenges getting medications approved by insurance. As such, there are fewer treatment options for children.”

Dosing and medication considerations

Another challenge dermatologists must consider, according to Dr. Carlberg, is the optimal dosing and route of administration for systemic medications. Pediatric patients require weight-based dosing, necessitating medication adjustments as they grow.

“For example, dupilumab is a systemic medication used to treat atopic dermatitis,” she said. “Although there is one dosage regimen in adults, the dosing varies based on age and weight in children.”

Taking one’s medicine

Finally, another factor in managing pediatric patients with skin diseases is the fact that many children are unable to take oral pills, tolerate injected medications, or withstand diagnostic tests such as patch testing or skin biopsies, Dr. Carlberg said.

This afternoon’s session will prepare for these challenges as well as the importance of partnering with parents.

“Parents are wonderful advocates for their children and are appropriately concerned about the safety and efficacy of the treatments we recommend. Whether discussing topical steroids for atopic dermatitis or FDA-approved oral propranolol for infantile hemangiomas in young infants, both can cause unease,” Dr. Carlberg said. “Additionally, many parents consume information from non-dermatologists via social media and other platforms and this can lead to confusion. As the skin experts, dermatologists have an opportunity to partner with parents to become aligned in the same goal of improving the child’s skin.”

Challenges to managing pediatric skin disease:

1. Pediatric population often excluded from clinical trials
2. Lack of approval by FDA and insurance
3. Weight-based dosing
4. A child’s inability to tolerate oral pills, injected medicines, and diagnostic tests

Kids will be kids. Yet treating their dermatologic conditions can be challenging when the model is designed for adults.
Easy does it
A more effective way to study for your board exam

Sima Jain, MD, FAAD, author of Dermatology: Illustrated Study Guide and Comprehensive Board Review

U023 – Board Review: Work Smarter, Not Harder
Friday, March 17 | 4:30-5:30 p.m. Location: New Orleans Theater B

There is a way to study for the board exam that doesn’t have to be stressful. Studying smarter helps you pass your board exam more easily but more importantly, also makes you a better dermatologist in the long run.”
—Sim a Jain, MD, FAAD

The dermatology board certification exam by the American Board of Dermatology is the testing pinnacle that challenges every dermatology resident. One of the most daunting challenges may not be the exam itself, however, but rather the stress and fear that accompanies the method by which many dermatology residents study for the exam.

“Don’t need to study harder to pass your boards with flying colors, you need to study smarter,” said Sima Jain, MD, FAAD, author of Dermatology: Illustrated Study Guide and Comprehensive Board Review, one of the most-read board review study guides. “There is a way to study for the board exam that doesn’t have to be stressful. Studying smarter helps you pass your board exam more easily but more importantly, also makes you a better dermatologist in the long run.”

In this afternoon’s session, “Board Review: Work Smarter, Not Harder,” Dr. Jain will discuss effective ways to prepare for the dermatology board exam. The key to acing your boards, she said, is not about memorizing details about skin conditions.

Deeper understanding required

The specialists who write board exam questions aren’t looking for rote memorization. Dr. Jain explained. They are looking for understanding — the ability to synthesize patient history, visual clues, and clinical elements to guide clinical decisions.

“Learning the buzzwords does not mean you understand the disease,” Dr. Jain said. “Dermatology residents are bright. They are used to being the top of the top students and often do very well on exams. However, this exam is different. Passing the board exam is about understanding information, not memorizing more information. Focusing on effectively understanding the different aspects of skin disease from the start is less stressful than trying to cram more facts into your head. And you will be much more successful when you finally sit for your exam.”

The smarter, more effective way to study is to go through multiple question and answer banks and boards study charts to determine your own strengths and weaknesses to guide and focus your study. It is an important way to gauge if you truly understand the material and make sure you are truly translating everything you have learned to help your real-life clinical acumen. Spending more time with skin atlases can also improve understanding and illustrate diagnostic clues that can be difficult to understand in text form.

Picture this
It helps to review as many photographs of skin conditions as in many different skin tones as possible. Some dermatology training programs have the benefit of an ethnically diverse patient population. Other programs may not be home to a population that is as diverse, which can leave residents unsure when examining skin of color, as skin conditions look different in different skin tones.

“I trained in Chicago, and our patients were ethnically diverse, but if you haven’t had that kind of background during training, you could miss a diagnosis because a rash might not look the same in a patient with skin of color. This is where photos can help supplement your clinical training. It all comes back to being a good dermatologist,” Dr. Jain said. “And this way, you’re not studying harder, you’re studying smarter.”

“Studying smarter takes a lot of angst out of the board exam,” she said. “That exam is just one day, and we want you to pass with flying colors. We also want you to pass with flying colors every single day while you’re practicing. You can meet both of those goals by studying smarter.”

The AAD has curated an extensive list of resources for boards study at www.aad.org/education/residents/external. The AAD also has a large archive of boards folder study charts at www.aad.org/boardsfolder.
Experience real patient stories about Adbry

Take a stroll through our patient gallery where you’ll see and hear from real Adbry patients

EXPLORE THE PATIENT GALLERY
AT BOOTH 3739

Scan to see where we’re at
While in New Orleans, join LEO Pharma for the grand unveiling of

The Museum of Dermatologic ADvancement (MoDA)

A carefully curated interactive experience in moderate-to-severe atopic dermatitis

Explore our special exhibit featured at MoDA

Looking Ahead and Giving Back

Leave your mark on the moderate-to-severe atopic dermatitis community with a unique opportunity to benefit Camp Discovery—A life-changing summer camp experience where kids with chronic skin conditions make friends, find acceptance, and are free to be themselves.

Get your stamp and help give back to patients at BOOTH 3739
During your visit at MoDA...

Immerse yourself in an IL-13 exhibit

Take an in-depth look at the role of IL-13 in atopic dermatitis

JOIN US AT BOOTH 3739

LEO Pharma Inc.

Scan for directions to our booth
The breast is yet to come (to your office)

Dermatologists should be ready to treat skin diseases of the breast.

When was the last time you saw a patient with idiopathic granulomatous mastitis? For many dermatologists, the answer is “never,” even though this inflammatory disease of breast skin is treated with familiar, anti-inflammatory agents.

“There are conditions like idiopathic granulomatous mastitis that breast surgeons see more than we do,” said Miriam K. Pomeranz, MD, FAAD, associate professor of dermatology at New York University Grossman School of Medicine and chief of dermatology at Bellevue Hospital. She and a panel of other experts will present the new session, “Behind the Bra: What Dermatologists Should Know About Diseases of the Breast” today at 1 p.m.

Sensitive sites

“Breast surgeons are the most common clinicians involved, but dermatologists can step in and be very helpful,” Dr. Pomeranz said. “And there are fewer common conditions like diffuse dermal angiomatosis, but pendulous breasts are a common site. It can cause significant discomfort and can look like inflammatory breast cancer, but it’s a dermatologic condition, just one of many skin diseases of the breast that are likely under-recognized.”

Gender issues

Inflammatory diseases of the breast as well as infectious and neoplastic entities affect many dermatology patients. Procedures most often seen in patients who are transgender or gender non-binary can have dermatologic sequelae.

“Transgender men sometimes bind their breasts to appear more masculine, which can lead to dermatitis,” Dr. Pomeranz noted. “People having top surgery can become very self-conscious about the scarring, and dermatologists are the leading experts in minimizing and treating scars. That’s just one set of many areas we are becoming involved in — or should be.”

Pregnancy, lactation, and other issues

Pregnancy and lactation also increase the likelihood of dermatitis. Breast size typically increases, which can lead to skin problems, particularly irritant dermatitis. Lactation can also give rise to discomfort, irritation, and infection.

“There are other complications that we don’t often think about, like Raynaud’s syndrome,” Dr. Pomeranz said. “We tend to think about Raynaud’s and fingers or toes, but it can occur in the breast as well, leading to a lot of pain and discoloration. Clinicians aren’t always aware that it can happen outside the digits.”

Dermatologists occasionally diagnose breast cancers that present as eczema of the nipple, but they more often see the side effects of chemotherapy or radiation therapy that affect the breast.

Radiation dermatitis can be very uncomfortable, Dr. Pomeranz said, as can post-radiation morphea. Morphea often occurs on the breast but can occur elsewhere as well. Dermatologists are frequently called in to help deal with scarring after breast cancer surgery.

“Patients, particularly women, may be hesitant to discuss or show the dermatologist diseases on the breast,” Dr. Pomeranz said. “They may not initially take their bra off for an exam, so we need to get more comfortable with asking directly if they are having any pain or discomfort. This session will help you get more comfortable with asking about and treating the skin of the breast, including some of the more unusual presentations that may walk into your office.”
TREAT RENEW PROTECT MOISTURIZE CLEANSE

Strategic use of OTC skincare, including gentle cleansers and moisturizers, can promote adherence by improving tolerability 2,3

In a study of patients with acne, almost 40% of treatment non-adherence was due to side effects 1

Strategic use of OTC skincare, including gentle cleansers and moisturizers, can promote adherence by improving tolerability 2,3


© Johnson & Johnson Consumer Inc. 2023. 88607 01/23 Printed in USA
Don’t miss the AAD Career Networking Event!

The search is on for your future in dermatology.

AAD Career Networking Event
Friday, March 17 | 4:30–6:30 p.m.
Location: Hilton New Orleans Riverside Hotel, Grand Ballroom C

If you’re hunting for a dermatology job or are about to graduate, we recommend you do not miss the AAD Career Networking Event! The AAD Career Networking Event is a great, high-energy opportunity to meet over 50 employers, face-to-face in a dedicated two-hour setting. Drinks will be provided as you meet and mingle with potential employers from all over the country and network with other dermatologists.

Register today to stay in the know!

This event is supported by DermCare Management.

Imagine the impact alopecia areata has on your patients

Alopecia areata affects an estimated 1.5 million Americans at any given time and can be debilitating to their physical and mental health.

The SALT score is used to assess scalp hair loss in clinical trials. A higher score means less scalp hair and the potential for significant psychosocial impact.

Ask us about the SALT score. Find out how a lower score can make all the difference in a patient’s life.

CoNCErT Pharmaceuticals Inc.
Alopecia Areata
KNOW THE SCORE
Visit us at Stand 1534
Meet Spot!

and learn how our AI augmented formulations represent the future of skin care.

Booth 630
OTEZLA® (apremilast) 30mg tablets

© 2023 Amgen Inc. All rights reserved.
OTEZLA® (APREMILAST) WELCOMES YOU TO THE 2023 AAD ANNUAL MEETING!

Looking for a different path for your patients?

DON'T WAIT

Learn more about the Otezla trail.

VISIT US AT BOOTH 1942
Exhibit Hall map

Exhibitor Listing

Data current as of February 21, 2023. Please use the AAD Meeting App aad.org/mobile for the most up-to-date exhibitor list.
Exhibit Hall hours
Friday – Saturday | 10 a.m.–5 p.m.
Sunday | 10 a.m.–3 p.m.
SEE WHAT’S POSSIBLE

VISIT US AT ABBVIE BOOTH #1642

Can’t wait? Learn more now at www.SkyriziHCP.com
**EXHIBITOR LISTING**

Continued from page 15

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrogena</td>
<td>3113</td>
</tr>
<tr>
<td>National Psoriasis Foundation</td>
<td>213</td>
</tr>
<tr>
<td>NAOS/Laboratoire Bioderma</td>
<td>3919</td>
</tr>
<tr>
<td>MotherToBaby Pregnancy Studies</td>
<td>920</td>
</tr>
<tr>
<td>Lassenview</td>
<td>954</td>
</tr>
<tr>
<td>LC Cell</td>
<td>248</td>
</tr>
<tr>
<td>LearnSkin</td>
<td>3529</td>
</tr>
<tr>
<td>Leaster</td>
<td>3755</td>
</tr>
<tr>
<td>LEO Pharma</td>
<td>3739</td>
</tr>
<tr>
<td>Lilly USA, LLC</td>
<td>1052</td>
</tr>
<tr>
<td>Loks of Love, Inc.</td>
<td>4329</td>
</tr>
<tr>
<td>L’Oréal Dermatological Beauty</td>
<td>542</td>
</tr>
<tr>
<td>Lumenis</td>
<td>1542</td>
</tr>
<tr>
<td>LUMISQUE</td>
<td>984</td>
</tr>
<tr>
<td>LUTRONIC</td>
<td>1914</td>
</tr>
<tr>
<td>Marshfield Clinic Health System</td>
<td>1368</td>
</tr>
<tr>
<td>McGraw Hill</td>
<td>4216</td>
</tr>
<tr>
<td>MD Charts</td>
<td>2127</td>
</tr>
<tr>
<td>MD Cosmetica</td>
<td>1734</td>
</tr>
<tr>
<td>Medisystems</td>
<td>3820</td>
</tr>
<tr>
<td>Medisolutions</td>
<td>3721</td>
</tr>
<tr>
<td>Medax Laser</td>
<td>592</td>
</tr>
<tr>
<td>Medical USA</td>
<td>2654</td>
</tr>
<tr>
<td>Medlase LLC</td>
<td>770</td>
</tr>
<tr>
<td>Mediloupes</td>
<td>962</td>
</tr>
<tr>
<td>Meditome Co Ltd</td>
<td>557</td>
</tr>
<tr>
<td>Medjet</td>
<td>1065</td>
</tr>
<tr>
<td>Medline Industries, LP</td>
<td>4629</td>
</tr>
<tr>
<td>Merck</td>
<td>1947</td>
</tr>
<tr>
<td>Messesetic Sl</td>
<td>3549</td>
</tr>
<tr>
<td>MetaOptima Technology Inc</td>
<td>453</td>
</tr>
<tr>
<td>Microsurgery Instruments, Inc</td>
<td>2218</td>
</tr>
<tr>
<td>Mid Florida Dermatology &amp; Plastic Surgery</td>
<td>2356</td>
</tr>
<tr>
<td>Midmark Corporation</td>
<td>1434</td>
</tr>
<tr>
<td>MiraDry, Inc</td>
<td>318</td>
</tr>
<tr>
<td>MIPP Capital</td>
<td>1052</td>
</tr>
<tr>
<td>Modernizing Medicine, Inc</td>
<td>4393</td>
</tr>
<tr>
<td>MotherToBaby Pregnancy Studies</td>
<td>920</td>
</tr>
<tr>
<td>MtI, Inc.</td>
<td>1634</td>
</tr>
<tr>
<td>MyDermRecruit/MyMDRecruit</td>
<td>1067</td>
</tr>
<tr>
<td>NAOS/Laboratoire Bioderma</td>
<td>3919</td>
</tr>
<tr>
<td>National Erzema Association</td>
<td>2328</td>
</tr>
<tr>
<td>National Porsiosis Foundation</td>
<td>213</td>
</tr>
<tr>
<td>NeoStrata Company, Inc</td>
<td>3127</td>
</tr>
<tr>
<td>Neutrogena</td>
<td>3113</td>
</tr>
<tr>
<td>Newmedical Technology, Inc</td>
<td>4431</td>
</tr>
<tr>
<td>Nextech</td>
<td>2280</td>
</tr>
</tbody>
</table>

**Support the cause: Scan your badge, stamp your passport**

**Look for this icon**

Visit each AAD Cause Supporter’s booth, get your badge scanned and passport stamped, and they will donate $100 for every scan.

**Enter to win!**

Bring your completed passport to the AAD Resource Center Booth 4039 by 3 p.m. Sunday, March 19 for your chance to win complimentary registration to the 2024 AAD Annual Meeting Registration in San Diego. PLUS, the first 500 participants will receive a special gift. Some exclusions apply. For a listing of all drawing rules and eligible participants, visit www.aad.org/support-cause.

**Attend today’s QI symposium**

**5019 - The Quality Improvement and Innovation Symposium**

Friday, March 17 | 1–4 p.m. Room: Location 397

The symposium showcases real-life examples of QI and provides a framework for how quality improvements can be incorporated into dermatologists’ daily practice.

The symposium will feature guest speaker, Brent James, MD, MStat, FACPE, clinical professor at the Clinical Excellence Research Center at Stanford University School of Medicine.

We encourage attendance at today’s 5019 - The Quality Improvement and Innovation Symposium from 1–4 p.m. in Room 288.

**Remember to use the American Academy of Dermatology’s (AAD) online Continuing Professional Development Transcript (CPD) Program to document your CME and MOC activities to send to a licensing body. This service is a member benefit at no additional fee.”**

* Excludes Adjunct and Corporate Individual Members

**AbbVie:** Supporters of AAD Philanthropic Programs as a top sponsor of the President’s Gala, Booth 1642

**DermTech:** Supporters of AAD Skin Cancer Awareness, Booth 2839

**LEO Pharma:** Supporters of AAD Camp Discovery, Booth 3739

**Sanofi and Regeneron:** Supporters of AAD Camp Discovery as a top sponsor of the President’s Gala, Booth 342

**Support the cause: Scan your badge, stamp your passport**

**Look for this icon**

Visit each AAD Cause Supporter’s booth, get your badge scanned and passport stamped, and they will donate $100 for every scan.

**Enter to win!**

Bring your completed passport to the AAD Resource Center Booth 4039 by 3 p.m. Sunday, March 19 for your chance to win complimentary registration to the 2024 AAD Annual Meeting Registration in San Diego. PLUS, the first 500 participants will receive a special gift. Some exclusions apply. For a listing of all drawing rules and eligible participants, visit www.aad.org/support-cause.

**Attend today’s QI symposium**

**5019 - The Quality Improvement and Innovation Symposium**

Friday, March 17 | 1–4 p.m. Room: Location 397

The symposium showcases real-life examples of QI and provides a framework for how quality improvements can be incorporated into dermatologists’ daily practice.

The symposium will feature guest speaker, Brent James, MD, MStat, FACPE, clinical professor at the Clinical Excellence Research Center at Stanford University School of Medicine.

We encourage attendance at today’s 5019 - The Quality Improvement and Innovation Symposium from 1–4 p.m. in Room 288.

The symposium showcases real-life examples of QI and provides a framework for how quality improvements can be incorporated into dermatologists’ daily practice.

The symposium will feature guest speaker, Brent James, MD, MStat, FACPE, clinical professor at the Clinical Excellence Research Center at Stanford University School of Medicine, and renowned for his work in clinical quality improvement, patient safety, and structures underlying successful improvement efforts. He will present “ Profession-Based Medicine: The Best Clinical Result at the Lowest Necessary Cost.”

The AAD’s Resident Quality Improvement Award recipients and the AAD’s Innovations in Quality Improvement Award recipients will also present during the symposium.

**Support the cause: Scan your badge, stamp your passport**

**Look for this icon**

Visit each AAD Cause Supporter’s booth, get your badge scanned and passport stamped, and they will donate $100 for every scan.

**Enter to win!**

Bring your completed passport to the AAD Resource Center Booth 4039 by 3 p.m. Sunday, March 19 for your chance to win complimentary registration to the 2024 AAD Annual Meeting Registration in San Diego. PLUS, the first 500 participants will receive a special gift. Some exclusions apply. For a listing of all drawing rules and eligible participants, visit www.aad.org/support-cause.

**Attend today’s QI symposium**

**5019 - The Quality Improvement and Innovation Symposium**

Friday, March 17 | 1–4 p.m. Room: Location 397

The symposium showcases real-life examples of QI and provides a framework for how quality improvements can be incorporated into dermatologists’ daily practice.

The symposium will feature guest speaker, Brent James, MD, MStat, FACPE, clinical professor at the Clinical Excellence Research Center at Stanford University School of Medicine.

We encourage attendance at today’s 5019 - The Quality Improvement and Innovation Symposium from 1–4 p.m. in Room 288.

The symposium showcases real-life examples of QI and provides a framework for how quality improvements can be incorporated into dermatologists’ daily practice.

The symposium will feature guest speaker, Brent James, MD, MStat, FACPE, clinical professor at the Clinical Excellence Research Center at Stanford University School of Medicine, and renowned for his work in clinical quality improvement, patient safety, and structures underlying successful improvement efforts. He will present “ Profession-Based Medicine: The Best Clinical Result at the Lowest Necessary Cost.”

The AAD’s Resident Quality Improvement Award recipients and the AAD’s Innovations in Quality Improvement Award recipients will also present during the symposium.

**Support the cause: Scan your badge, stamp your passport**

**Look for this icon**

Visit each AAD Cause Supporter’s booth, get your badge scanned and passport stamped, and they will donate $100 for every scan.

**Enter to win!**

Bring your completed passport to the AAD Resource Center Booth 4039 by 3 p.m. Sunday, March 19 for your chance to win complimentary registration to the 2024 AAD Annual Meeting Registration in San Diego. PLUS, the first 500 participants will receive a special gift. Some exclusions apply. For a listing of all drawing rules and eligible participants, visit www.aad.org/support-cause.
Informing decisions, improving outcomes

DecisionDx®-Melanoma is the first and only melanoma prognostic test associated with improved patient outcomes. By integrating a patient’s tumor biology with clinical and pathologic factors, DecisionDx-Melanoma precisely predicts individual risk of metastasis, SLN positivity, and recurrence. The comprehensive and personalized results help to improve prognostic accuracy, better inform patient management decisions, and positively impact outcomes.

Tumor Biology Matters.
CastleTestInfo.com/ImprovingOutcomes

Visit us at Booth 4051
How are you feeling today?

New session urges emotional check-in treating patients with hair, scalp, and nail disorders.

Putting a microscope on the diagnoses and treatment of hair, scalp, and nail disorders is a dermatologist’s natural inclination. However, a close-up examination of a patient’s emotional view of the disorder and the impact it may have on their quality of life should also be one of the first steps in managing patient care.

Although the primary focus of the session offers a practical guide for the treatment of hair, scalp, and nail disorders, session co-director Antonella Tosti, MD, said dermatologists must have a thorough understanding of how the disease affects the patient’s everyday life. Dr. Tosti is a professor of dermatology at the University of Miami Miller School of Medicine. She is joined by co-director Brian William Morrison, MD, MSc, FAAD, also a professor of dermatology at the University of Miami Miller School of Medicine.

Although designed to educate young physicians, the Saturday session will provide an up-to-date review of hair, scalp, and nails that all dermatologists will find of value.

A more comprehensive understanding of patients and their disorders

“Disorders of hair and nails create a big impact on the quality of life of patients as they are very visible and create anxiety and depression,” Dr. Tosti said. “Although these diseases are part of dermatology training during residency, it is often not extensive, and many dermatologists are not very familiar with diagnostic procedures and new treatments.”

Progressing to the next step and applying new as well as tried-and-true treatments can likely change the course of the disease as well as the patient’s emotional well-being, she said.

Utilize dermoscopy in all patients with hair and nail disorders, not only to evaluate the disease better, but also to take the biopsy in the most active area. Use your dermatoscope in the case of scalp injections to see which areas need to be treated. Always discuss in depth possible side effects of any treatment to make a decision together with your patient.”

– Antonella Tosti, MD

New drugs provide new promise

The latest treatments, including JAK inhibitors, are effective and represent a new option for alopecia areata, Dr. Tosti said, but also show potential for other hair disorders. JAK inhibitors can also be successfully used for some inflammatory nail disorders. Additionally, there are new ways of delivering existing drugs such as minoxidil that can be used as an oral medication or as intralesional administration. Oral minoxidil has recently shown promise in accelerating nail growth rate and can be useful in treating nail disease, she said.

Central centrifugal cicatricial alopecia at dermoscopy

Regardless of the treatment, Dr. Tosti said teledermatology can be a good tool to discuss how the patient is compliant with treatment and possible side effects before an in-person follow-up evaluation.

Covering everything from head to toe

Saturday’s session will also explore the use of platelet-rich plasma, microneedling, and intra-lesional injections.

“These are complements to medical treatment and not an alternative,” Dr. Tosti said. “This is important to be clarified to patients who often prefer procedures to treatments they have to do themselves at home. All these procedures improve treatment outcomes and are recommended in association with medical therapy.”

Finally, Dr. Tosti said Saturday’s panel will address how gender and ethnicity effect treatment of hair, scalp, and nail disorders. Some hair and nail diseases have a different frequency depending on ethnicity because of genetic factors or exposure to different triggering factors, she said. Recognizing hair type is essential for haircare recommendations. Instance evaluation of nail pigmentation requires greater attention in patients with dark phototypes. For example, melanoma of the nail is more common in this population.

Although designed to educate young physicians, the Saturday session will provide an up-to-date review of hair, scalp, and nails that all dermatologists will find of value.
In DERMIS-1 and DERMIS-2, ~40% of patients achieved IGA Success and ~70% of patients achieved I-IGA Success at Week 8. ¹

DERMIS-1 and DERMIS-2 were identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multicenter studies that evaluated ZORYVE over 8 weeks as a once-daily, topical treatment for plaque psoriasis. Subjects (N=881) were randomized 2:1 to receive ZORYVE cream 0.3% (n=576) or vehicle (n=305) applied once daily for 8 weeks. Eligibility criteria included a diagnosis of mild, moderate, or severe plaque psoriasis and an affected BSA of 2% to 20%. Primary endpoint was IGA Success at Week 8 and key secondary endpoint was I-IGA Success at Week 8. ¹

IGA Success was defined as a score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline. I-IGA Success was defined as a score of Clear (0) or Almost Clear (1) and ≥2-grade improvement from baseline. ZORYVE is not for ophthalmic, oral, or intravaginal use.

BSA = Body Surface Area, IGA = Investigator’s Global Assessment, I-IGA = Intertriginous-IGA

¹ ZORVYE®. Prescribing information. Arcutis Biotherapeutics, Inc; 2022.

² Data on File. Arcutis Biotherapeutics, Inc.
In DERMIS-1 and DERMIS-2, ~40% of patients achieved IGA Success and ~70% of patients achieved I-IGA Success at Week 8. 1

See the results at zoryvehcp.com

DERMIS-1 and DERMIS-2 were identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multicenter studies that evaluated ZORYVE over 8 weeks as a once-daily, topical treatment for plaque psoriasis. Subjects (N=881) were randomized 2:1 to receive ZORYVE cream 0.3% (n=576) or vehicle (n=305) applied once daily for 8 weeks. Eligibility criteria included a diagnosis of mild, moderate, or severe plaque psoriasis and an affected BSA of 2% to 20%. Primary endpoint was IGA Success at Week 8 and key secondary endpoint was I-IGA Success at Week 8. 1

IGA Success was defined as a score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline. I-IGA Success was defined as a score of Clear (0) or Almost Clear (1) and ≥2-grade improvement from baseline.

ZORYVE is not for ophthalmic, oral, or intravaginal use.

BSA = Body Surface Area, IGA = Investigator’s Global Assessment, I-IGA = Intertriginous-IGA

INDICATION
ZORYVE is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION
The use of ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). The most common adverse reactions (≥1%) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%).

Please see brief summary of full Prescribing Information for ZORYVE on the following page.

**Brief Summary of Prescribing Information for ZORYVE™ (roflumilast) cream, for topical use. See package insert for full Prescribing Information.**

**INDICATIONS AND USAGE**

ZORYVE is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.

**DOSAGE AND ADMINISTRATION**

Apply ZORYVE to affected areas once daily and rub in completely. Wash hands after application, unless ZORYVE is for treatment of the hands.

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.

**CONTRAINDICATIONS**

The use of ZORYVE is contraindicated in the following condition:

- Moderate to severe liver impairment (Child-Pugh B or C)

**ADVERSE REACTIONS**

**Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two multicenter, randomized, double-blind, vehicle-controlled trials (DERMIS-1 and DERMIS-2), 881 subjects 2 years of age or older with plaque psoriasis were treated with ZORYVE or vehicle once daily for 8 weeks.

The median age was 47 years (range 6 to 88). The majority of the subjects were male (64%) and White (82%). The median body surface area (BSA) affected was 5.5% (range 2% to 20%).

The proportion of subjects who discontinued treatment due to adverse reaction was 1.0% for subjects treated with ZORYVE and 1.3% for subjects treated with vehicle. The most common adverse reactions that led to discontinuation of ZORYVE was application site urticaria (0.3%).

Table 1 presents adverse reactions that occurred in at least 1% of subjects treated with ZORYVE, and for which the rate exceeded the rate for vehicle.

**Table 1. Adverse Reactions Reported in ≥1% of Subjects Treated with ZORYVE for 8 Weeks**

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>ZORYVE (N=576) n (%)</th>
<th>Vehicle (N=305) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>18 (3.1)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>14 (2.4)</td>
<td>3 (1.0)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>8 (1.4)</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Nausea</td>
<td>7 (1.2)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Application site pain</td>
<td>6 (1.0)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>6 (1.0)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>6 (1.0)</td>
<td>2 (0.7)</td>
</tr>
</tbody>
</table>

In 594 subjects who continued treatment with ZORYVE for up to 64 weeks in open-label extension trials, the adverse reaction profile was similar to that observed in vehicle-controlled trials.

**USE IN SPECIFIC POPULATIONS**

**Pregnancy**

**Risk Summary**

There are no randomized clinical trials of oral or topical roflumilast in pregnant women. In animal reproduction studies, roflumilast administered orally to pregnant rats and rabbits during the period of organogenesis produced no fetal structural abnormalities at doses up to 9 and 8 times the maximum recommended human dose (MRHD), respectively. Roflumilast induced post-implantation loss in rats at oral doses greater than or equal to 3 times the MRHD. Roflumilast induced stillbirth and decreased pup viability in mice at oral doses 5 and 15 times the MRHD, respectively. Roflumilast has been shown to adversely affect pup post-natal development when dams were treated with an oral dose 15 times the MRHD during pregnancy and lactation periods in mice.

The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

**Clinical Considerations**

**Labor and delivery**

ZORYVE should not be used during labor and delivery. There are no human studies that have investigated effects of ZORYVE on preterm labor or labor at term; however, animal studies showed that oral roflumilast disrupted the labor and delivery process in mice.

**Data**

**Animal data**

In an embryo-fetal development study, pregnant rats were dosed orally during the period of organogenesis with up to 1.8 mg/kg/day roflumilast (9 times the MRHD on a mg/m² basis). No evidence of structural abnormalities or effects on survival rates were observed. Roflumilast did not affect embryo-fetal development at a maternal oral dose of 0.2 mg/kg/day (equivalent to the MRHD on a mg/m² basis).

In a fertility and embryo-fetal development study, male rats were dosed orally with up to 1.8 mg/kg/day roflumilast for 10 weeks and females for 2 weeks prior to pairing and throughout the organogenesis period. Roflumilast induced pre- and post-implantation loss at maternal oral doses greater than or equal to 0.6 mg/kg/day (3 times the MRHD on a mg/m² basis). Roflumilast did not cause fetal structural abnormalities at maternal oral doses up to 1.8 mg/kg/day (9 times the MRHD on a mg/m² basis).

In an embryo-fetal development study in rabbits, pregnant does were dosed orally with 0.8 mg/kg/day roflumilast during the period of organogenesis. Roflumilast did not cause fetal structural abnormalities at the maternal oral doses of 0.8 mg/kg/day (8 times the MRHD on a mg/m² basis).

In pre- and post-natal developmental studies in mice, dams were dosed orally with up to 12 mg/kg/day roflumilast during the period of organogenesis and lactation. Roflumilast induced stillbirth and decreased pup viability at maternal oral doses greater than 2 mg/kg/day and 6 mg/kg/day, respectively (5 and 15 times the MRHD on a mg/m² basis, respectively). Roflumilast induced delivery retardation in pregnant mice at maternal oral doses greater than 2 mg/kg/day (5 times the MRHD on a mg/m² basis). Roflumilast decreased pup rearing frequencies at a maternal oral dose of 6 mg/kg/day during pregnancy and lactation (15 times the MRHD on a mg/m² basis). Roflumilast also decreased survival and forelimb grip reflex and delayed pinna detachment in mouse pups at a maternal oral dose of 12 mg/kg/day (29 times the MRHD on a mg/m² basis).

**Lactation**

**Risk Summary**

There is no information regarding the presence of ZORYVE in human milk, the effects on the breastfed infant, or the effects on milk production.

Roflumilast and/or its metabolites are excreted into the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZORYVE and any potential adverse effects on the breastfed infant from ZORYVE or from the underlying maternal condition.

**Clinical Considerations**

To minimize potential exposure to the breastfed infant via breast milk, use ZORYVE on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply ZORYVE directly to the nipple and areola to avoid direct infant exposure.

**Data**

**Animal data**

Roflumilast and/or its metabolite concentrations measured 8 hours after an oral dose of 1 mg/kg given to lactating rats were 0.32 and 0.02 mcg/g in the milk and pup liver, respectively.

**Pediatric Use**

The safety and effectiveness of ZORYVE have been established in pediatric patients ages 12 years and older for the treatment of plaque psoriasis. Use of ZORYVE in this age group is supported by data from two 8-week vehicle-controlled safety and efficacy trials which included 14 adolescent patients aged 12 to 17 years, of whom 8 received ZORYVE. Eighteen adolescent patients were treated with ZORYVE in open-label trials of 2- and 24-weeks duration. The adverse reaction profile was similar to that observed in adults.

The safety and effectiveness of ZORYVE in pediatric patients below the age of 12 years have not been established.

**Geriatric Use**

Of the 881 subjects with psoriasis exposed to ZORYVE or vehicle for up to 8 weeks in 2 controlled clinical trials, 106 were 65 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the geriatric and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Based on available data for roflumilast, no adjustment of dosage in geriatric patients is warranted.

**Hepatic Impairment**

Oral roflumilast 250 mcg once daily for 14 days was studied in subjects with hepatic impairment. The AUC and Cmax values of roflumilast and roflumilast N-oxide were increased in subjects with moderate (Child-Pugh B) hepatic impairment. ZORYVE is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C).

**PATIENT COUNSELING INFORMATION**

Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information).
Mirroring society in dermatology practice

Building a workforce that reflects those we serve

Jennifer Huang, MD, FAAD, chief of dermatology and director of pediatric oncodermatology at Boston Children’s Hospital and associate professor of dermatology at Harvard Medical School

Mayra Lorenzo, MD, PhD, FAAD, chair of the Harvard Dermatology Diversity Committee and assistant professor of dermatology at Harvard Medical School

The reality, she continued, is that the dermatology community does not mirror the diversity of the dermatology patient population. Not yet. A key strategy in the recruitment process is to offer resources and mentorship opportunities that are relevant to both the applicant’s identity and their career interests.

Residents leading the charge in Boston

Dermatology is also working upstream to expand opportunities for both residents and Boston-area communities. Residents lead multiple service-learning programs, including a high school STEM (science, technology, engineering, and mathematics) pathway program to encourage early interest in science and medicine and a student-run pediatric dermatology clinic.

“We incorporate experiences in caring for underserved populations into our standard clinical curriculum, including skin of color clinics and clinics that serve patients experiencing homelessness, Spanish- and Portuguese-speaking communities, and LGBTQ+ patients,” Dr. Lorenzo said. “Global integration of DEI initiatives within all areas of the program is best, in the classroom and in the clinics at every level,” she continued.

“Everyone — faculty, residents, fellows, and support staff — needs to learn more about how to create a diverse and inclusive community. It can be demoralizing for residents to receive this education and feel that nobody else is learning about or respecting the principles of DEI,” Dr. Huang said.

“Our work is definitely not done,” she said. “We have a lot to learn and hope we can form a closer community of educators who can work together on these important topics.”

See the future of dermatology recognized

The Residents and Fellows Symposium is an opportunity to hear about groundbreaking research performed by dermatology residents and fellows. The top 18 projects are selected from a pool of over 100 applicants to give succinct summaries of their research. Faculty judges selected individuals who presented the most outstanding papers in laboratory and clinical research. The Everett C. Fox Award (formerly the Stelwagon Award) is given to the presenters of the most outstanding clinical and laboratory research.

See the future of dermatology recognized

Don’t miss this exciting, inspiring, and instructive event! Winners of the Fox Award will be published in DermWorld Meeting News.

The Residents and Fellows Symposium is an opportunity to hear about groundbreaking research performed by dermatology residents and fellows. The top 18 projects are selected from a pool of over 100 applicants to give succinct summaries of their research. Faculty judges selected individuals who presented the most outstanding papers in laboratory and clinical research. The Everett C. Fox Award (formerly the Stelwagon Award) is given to the presenters of the most outstanding clinical and laboratory research.

Don’t miss this exciting, inspiring, and instructive event! Winners of the Fox Award will be published in DermWorld Meeting News.

Resident and Fellows Symposium

Saturday, March 18
9 a.m.–12 p.m.
Location: Room 291
Led by Cory A. Dunnick, MD, FAAD

MaineHealth Showcase

Maine Medical Partners is seeking a Board Certified/Board Eligible General Dermatologist to join their growing Dermatology practice in Portland, Maine. The dermatology clinics have state-of-the-art facilities with confocal microscopy, total body photography, phototherapy, Mohs surgery and dermatopathology in-house.

- You will be joining 6 BC dermatologists and 2 advanced practice providers.
- This is a full-time outpatient opportunity, with no inpatient call expectation.
- Full administrative and scribe support for your clinic.
- Physicians at MaineHealth are eligible for loan forgiveness under the Public Service Loan Forgiveness Program.

Interested candidates may submit a cover letter and CV to Linda Wiley at linda.wiley@mainehealth.org

Maine Medical Partners is seeking a Board Certified/Board Eligible General Dermatologist to join their growing Dermatology practice in Portland, Maine. The dermatology clinics have state-of-the-art facilities with confocal microscopy, total body photography, phototherapy, Mohs surgery and dermatopathology in-house.

- You will be joining 6 BC dermatologists and 2 advanced practice providers.
- This is a full-time outpatient opportunity, with no inpatient call expectation.
- Full administrative and scribe support for your clinic.
- Physicians at MaineHealth are eligible for loan forgiveness under the Public Service Loan Forgiveness Program.

Interested candidates may submit a cover letter and CV to Linda Wiley at linda.wiley@mainehealth.org

Maine Medical Partners is seeking a Board Certified/Board Eligible General Dermatologist to join their growing Dermatology practice in Portland, Maine. The dermatology clinics have state-of-the-art facilities with confocal microscopy, total body photography, phototherapy, Mohs surgery and dermatopathology in-house.

- You will be joining 6 BC dermatologists and 2 advanced practice providers.
- This is a full-time outpatient opportunity, with no inpatient call expectation.
- Full administrative and scribe support for your clinic.
- Physicians at MaineHealth are eligible for loan forgiveness under the Public Service Loan Forgiveness Program.

Interested candidates may submit a cover letter and CV to Linda Wiley at linda.wiley@mainehealth.org

Maine Medical Partners is seeking a Board Certified/Board Eligible General Dermatologist to join their growing Dermatology practice in Portland, Maine. The dermatology clinics have state-of-the-art facilities with confocal microscopy, total body photography, phototherapy, Mohs surgery and dermatopathology in-house.

- You will be joining 6 BC dermatologists and 2 advanced practice providers.
- This is a full-time outpatient opportunity, with no inpatient call expectation.
- Full administrative and scribe support for your clinic.
- Physicians at MaineHealth are eligible for loan forgiveness under the Public Service Loan Forgiveness Program.

Interested candidates may submit a cover letter and CV to Linda Wiley at linda.wiley@mainehealth.org

Maine Medical Partners is seeking a Board Certified/Board Eligible General Dermatologist to join their growing Dermatology practice in Portland, Maine. The dermatology clinics have state-of-the-art facilities with confocal microscopy, total body photography, phototherapy, Mohs surgery and dermatopathology in-house.

- You will be joining 6 BC dermatologists and 2 advanced practice providers.
- This is a full-time outpatient opportunity, with no inpatient call expectation.
- Full administrative and scribe support for your clinic.
- Physicians at MaineHealth are eligible for loan forgiveness under the Public Service Loan Forgiveness Program.

Interested candidates may submit a cover letter and CV to Linda Wiley at linda.wiley@mainehealth.org
Transcending burnout
Find the path to joy and a fuller life

It’s 2023 and physicians are becoming burned out on the topic of professional burnout. The truth is: the structure of the health care system and its impact on physician well-being is unlikely to change. But physicians can change the course of their own, personal journey, according to Kelly M. Cordoro, MD, FAAD, professor of dermatology and pediatrics at the University of California, San Francisco.

Dr. Cordoro is moving the discussion away from the structural and institutional causes of burnout to the individual journey in achieving joy. She leads a robust dialogue on the topic during Saturday’s session, “F063 – Self Care in Healthcare: Beyond Burnout to Finding Fulfillment.” Even with an array of wellness initiatives in place, physicians remain exhausted and disengaged.

“When our values and beliefs are aligned with our work, there is deep meaning and career/work satisfaction despite structural obstacles and frustrations. In contrast to the many medical professionals who are deeply satisfied and enriched by their work, there are some who are not. We have the power to change that, and it largely comes from within,” Dr. Cordoro said.

Self-reflection can be empowering
Dr. Cordoro believes that the same forces that shape us as people shape us as doctors. “Our circle of influence includes our core beliefs, experiences, perspectives, and environment.” In medicine, physicians face tremendous pressure to “conform and fall in line as we march along the training and career path largely under the influence of others.” Everyone in our professional circle, from colleagues and supervisors to role models and mentors, will influence our decisions and activities.

There is always an opportunity to reshape your career and life by figuring out who you are and what brings you meaning, she said. Of course, it requires a willingness and the time to take a deep personal dive into what brought you to medicine in the first place, the areas that feel energizing, and those that feel stifling.

“Honest self-appraisal is the first step to developing a true understanding of our personal values and beliefs and aligning our choices and actions accordingly. This work is empowering, and can be life- and career-altering, in a good way!” Dr. Cordoro said.

Keep pace with your personal journey
There are big and small ways to create change. It starts with “rethinking your focus and rearranging your plate toward a more favorable balance,” Dr. Cordoro said. Session speaker and Batavia, Illinois clinical psychologist Amy MacDonald, PsyD, will present attendees with a self-reflection exercise designed to identify core values and gain perspectives and skills to increase fulfillment and meaning in work and life. The session goals are:

- Determine which of your beliefs and actions are productive and bring joy/satisfaction and which may sustain a destructive or unhealthy pattern.
- Develop skills and perspectives that restore meaning in your work by realigning your work with your core values.
- Distinguish between environmental and host factors that contribute to joy or dissatisfaction.

Environmental factors are the systems, structures, organizations, people, and culture around us that influence us, while host factors are intrinsic to the person.

Burnout versus wellness
This afternoon’s session is not a session on burnout, Dr. Cordoro warned. Rather, the session focuses on the “deeply personal and dynamic nature of individual perspectives, values, and the road to joy in work and life.”

“Our personal impressions of well-being, our perspectives on work and life satisfaction, and our needs and wants change over time. Our view of well-being is shaped by our perceptions and the lens through which we view the world,” she said. “It is important to recognize that, and recognize that even though happiness is related to, and even used in some definitions of wellness, wellness as a concept is so much broader than happiness alone.”

Growth is a universal human value, and this afternoon’s session embraces a growth mindset.

“We cannot wait for the ‘big fix’ to the frustrating systemic issues we face in medicine, we must connect to core values,” Dr. Cordoro said. “Although access to outstanding occupational wellness programs to ameliorate ‘burnout’ abound, and can be helpful, true well-being starts from within.”

Today’s session will also discuss mental health, an important dialogue, given the prevalence of depression and suicide in medicine, including dermatology, she said.

“I truly think the session will be a change-maker for those who come prepared to take a reflective, deep dive into their own core values and start to align their choices with their self-identified drivers of joy and meaning,” she said.

Treating yourself so you can treat others better
Dermatologists and other health care workers are at an inflection point, and their health and well-being are on the line, according to Dr. Cordoro. Physicians are incredibly resilient and selfless and will rise to the occasion no matter what is asked of them, she said.

“This is great for your patients and teams but can be destructive to you as an individual. There’s no better time to afford ourselves time for self-reflection, personal awareness, and professional enrichment that goes beyond medical topics.”

“We level up and work harder, do more, and continue to give. But there is a breaking point. If you feel you are near it, or want to avoid it, attend this session. If you want to connect and reconnect with your core values, attend this session,” she said.
Good news! The ever-popular social media challenges will be returning to the AAD Annual Meeting in New Orleans. This year, there will be two different challenges that attendees can participate in — one on Twitter and one on Instagram. Both will offer the jealousy-inducing grand prize of free registration to the 2024 Annual Meeting in San Diego! Attendees are encouraged to participate in both challenges, and there is no limit to the number of entries submitted on either platform.

**Instagram Reel Challenge**

Gone are the days of posting selfies and photo carousels — video is the new way of sharing your best content on social media. We are asking attendees to share their Annual Meeting experience by creating an Instagram Reel of their time in The Big Easy with the hashtag #AAD2023challenge. Reels can be posted any time between Friday, March 17, and Tuesday, March 21, until 11:59 PM CDT. One grand prize winner will be randomly selected from the total submissions the following week and the reel will be shared from the @AADmember Instagram account.

**Twitter Pearl Challenge**

Twitter is still one of the most popular platforms for dermatologists to share research and discuss specialty topics. Since there is so much to learn about at the Annual Meeting, we are asking attendees to tweet their top pearls or key learnings from their favorite AAD sessions with the hashtag #AAD2023challenge to enter. One randomly chosen winner will be selected the week after the meeting ends.

For more information, see the official rules and regulations online at aadmeetingnews.org/22724379 or direct message @AADmember on Twitter or Instagram.
Novel therapies for alopecia areata are on the rise.

The FDA transformed the landscape for alopecia areata treatments last June with the approval of baricitinib— the first systemic treatment for the condition. The approval helped spur patients' already high interest in new and effective ways to treat hair loss.

Natasha Atanaskova Mesinkovska, MD, PhD, FAAD, professor of dermatology and vice chair for clinical research at the University of California Irvine School of Medicine, will direct this afternoon’s new symposium, “S058 - Alopecia Areata: New Therapies,” which will explore the latest approaches using baricitinib as well as other Janus kinase (JAK) inhibitors in the pipeline, and the latest in procedural and device-based approaches.

Medication for a specific disease

“Alopecia areata is the most common cause of immune-mediated alopecia,” said Dr. Mesinkovska. “Alopecia areata affects 2% of the U.S. population and is not a cosmetic issue. It is a specific autoimmune disease, and we finally have an approved medication with more on the way.”

Alopecia areata does not discriminate by sex or age, Dr. Mesinkovska said, and individuals of African American descent are somewhat more likely to present with this particular form of hair loss compared to those of Caucasian or Asian ethnicities. Women are somewhat more likely to seek treatment than men, maybe because men have the socially acceptable option of shaving their heads to avoid notice.

And unlike many forms of hair loss, alopecia areata can affect children and adolescents as well as adults. The average patient age is in the early 30s.

Finding alternatives

“Healthy hair is important for everyone, so it is vital to be able to identify alopecia areata quickly and correctly because we can treat it effectively with JAK inhibitors,” Dr. Mesinkovska said. “We don’t typically biopsy children, or even adults, if there is a good alternative, so we will have sessions on how to distinguish alopecia areata from other types of hair loss clinically and using dermoscopy. There are important tips to using dermoscopy as a tool to identify areata in all races and skin types because it can be tricky to differentiate.”

In addition to baricitinib, two other JAK inhibitors, ritlecitinib and deuruxolitinib, are in development. Patients who do not tolerate baricitinib or have adverse reactions may benefit from off-label use of an alternative agent. JAK inhibitors are relatively expensive and off-label reimbursement remains problematic.

Non-medical choices

There is also continuing interest in non-medication approaches to alopecia areata. Positive results have been reported for platelet rich plasma, microneedling, light treatments, and laser, although any subsequent hair growth varies by operator and patient factors. There is also the practical consideration of using relatively expensive, time-consuming, and sometimes painful temporary treatments for a chronic autoimmune disease.

Others slated to give presentations on a broad range of alopecia areata topics will be Brittany Gareth Craiglow, MD, FAAD, Chesahna Kindred, MD, MBA, FAAD, Brett Andrew King, MD, PhD, FAAD, Maryanne Makreides Senna, MD, FAAD, Jerry Shapiro, MD, FAAD, Bruna Duque Estrada, MD, and Ronda S. Farah, MD, FAAD.

“Attendees will leave this session better able to recognize tricky cases of alopecia areata, choose patients suitable for systemic therapy, and feel very comfortable using medications in both adults and children,” Dr. Mesinkovska said. “We have the best of the most-experienced alopecia areata speakers at this session to bring us up to date and to help us better treat and understand our patients.”

Headed in the right direction

Natasha Atanaskova Mesinkovska, MD, PhD, FAAD, professor of dermatology and vice chair for clinical research at the University of California Irvine School of Medicine
Hair loss isn’t the whole story.

• Alopecia areata (AA) is an autoimmune disease that can also have effects beyond the scalp.1
• AA has a complex etiology and is rooted in immune system dysregulation, with many patients having a genetic predisposition.2,3
• Patients often experience autoimmune and psychiatric comorbidities, lifestyle disruptions, and psychosocial distress.1,2,4
• The unpredictable course of AA can make disease management difficult for HCPs and their patients.5,6

References

To re-examine what you know about alopecia areata, visit education.lillymedical.com/advancesinaa